ArticleOncotarget2017

Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer.

Katie M Mishall et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.